Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study ...

Merck (Darmstadt, Germany) has launched its 2025 Curiosity Cube tour, aiming to bring hands-on STEM (science, technology, engineering, and mathematics) experiences to students across Europe, North ...

Merck said last week its biggest tariff exposure is through Keytruda and it has enough US inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.

Steps for how to make the background transparent in Photoshop Upload your image into Photoshop and then click Window and then check Layers if it doesn’t already have a tick next to it ...

In the release, Merck said this was a collaborative decision between the company and the program’s external steering committee. The phase 3 HYPERION trial of Winrevair in adults with newly ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF ...

Merck is not alone in the effort to bring bispecific antibodies to autoimmune disease. Roche’s mosunetuzumab, brand name Lunsumio, won approval two years ago as a treatment for follicular lymphoma.